Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers

Normal Healthy Volunteers Clinical Trial

Official title:
A Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers

Status Completed

Clinical Trial Summary

Study type: Interventional Description of intervention(s) / exposure For single ascending dose, five dose target ranges of BT-11 (depending on body weight the doses in each cohort will be 5.9 - 7.7 mg/kg; 18.9 - 25.0 mg/kg; 44.3 - 50.0 mg/kg; 68.5 - 75 mg/kg and 94.2 - 100.0 mg/kg) will be evaluated, based on subject's weight on Day 1. For multiple ascending dose (once daily for 7 days), three dose target ranges of BT-11 (depending on body weight the doses in each cohort will be 5.9 - 7.7 mg/kg; 44.3 - 50.0 mg/kg; and 94.2 - 100.0 mg/kg) will be evaluated, based on subject's weight on Day 1. White tablets containing 500 mg BT-11 or matching placebo tablets will be dispensed. Single ascending dose duration of administration will be once. For multiple ascending dose it will be up to 7 days. The mode administration will be oral tablet. Compliance and adherence to the intervention will be performed based on the tablet return, tablet not consumed by the subject. The safety monitoring committee will evaluate safety at conclusion of single ascending cohort 2 prior to the commencement of dosing for the multiple ascending dose.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Normal Healthy Volunteers

Clinical Trial Details

NCT number	NCT03860571
Study type	Interventional
Source	NImmune Biopharma
Contact
Status	Completed
Phase	Phase 1
Start date	July 6, 2018
Completion date	December 13, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05019950` - Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers	Phase 1
Completed	`NCT01366339` - Tolerance and Pharmacokinetics Study of MNTX Tablets	Phase 1
Completed	`NCT01862835` - Impact of Estradiol Addback	Phase 1
Completed	`NCT01629446` - Lofexidine Mass Balance in Volunteers	Phase 1
Completed	`NCT02026973` - Impact of Endogenous E2 on SSI and GH Rebound	Phase 1
Recruiting	`NCT03234504` - Development and Validation of a Novel Stereoacuity Test Using Head-mounted Display
Completed	`NCT04188730` - A Study Evaluating the Relative Bioavailability of Lofexidine Granules for Reconstitution Compared to LUCEMYRA (Lofexidine) Tablets and the Effect of Food on the Bioavailability of the Lofexidine Granules for Reconstitution	Phase 1
Completed	`NCT02271282` - Estradiol-Receptor Blockade in Older Men and Women	Phase 1
Withdrawn	`NCT03291158` - Safety and PK Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Minocin IV	Phase 1
Completed	`NCT02802631` - Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Minocin (Minocycline) for Injection in Healthy Adults	Phase 1